Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

ON Helix 2025

ON Helix 2025 will address key bio innovation trends, from developments in life science and technology research to their translation into new diagnostics, prevention tools [...]

Go to Top